The latest price update and price trend analysis of Tucatinib (Tucatinib) targeted drug in 2024

Tucatinib is a targeted drug used to treat HER2-positive breast cancer. Although it has not yet been launched in China, its market in Europe and other regions has matured. In 2024, the price of the original drug tucatinib in the European market will continue to be high. 150mg*84 tablets will cost about more than 40,000 yuan. This price positioning is mainly based on factors such as production costs, R&D investment, and patent protection of original drugs. Due to its unique efficacy and targeting mechanism, although this drug is expensive, it has a remarkable effect in treating patients with HER2-positive breast cancer, so it still attracts widespread attention.

Generic versions of tucatinib are significantly less expensive than the brand-name drug. Especially for generic drugs from Laos pharmaceutical factories, the price of 150mg*60 tablets is about more than 2,000 yuan. Although the price is cheap, the ingredients of generic drugs are basically the same as those of the original drugs, and there is no significant difference in the therapeutic effect. Because generic drugs can significantly reduce the financial burden on patients, they have become the choice of many patients, especially when original drugs are unavailable. With the popularity of generic drugs, the cost of tucatinib treatment has become more affordable for patients with limited financial resources.

Regarding the future price trend of tucatinib, the market is still in a period of volatility. Since the drug has not yet been approved in the Chinese market and cannot be included in the medical insurance system for the time being, it is expected that the price in the domestic market will still be difficult to fall in the short term. However, as time goes by and generic drugs are gradually promoted in other markets, the price of tucatinib in the domestic market may show a gradual downward trend. In addition, with the emergence of more targeted drugs and intensified competition, the prices of original drugs may be further reduced.

Overall, although tucatinib will still maintain a relatively high price in 2024 , with the introduction of generic drugs and intensified market competition, patients will be able to obtain the same efficacy at a lower price in the future. When choosing drugs, patients should reasonably choose original drugs or generic drugs based on their own economic conditions and doctor's advice. As tucatinib is promoted in the global market and production costs are further reduced, it is expected that the price of the drug will gradually become more affordable in the next few years.

Reference materials:https://www.tukysa.com/